Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants

Finding an effective human immunodeficiency virus type 1 (HIV-1) vaccine remains a major global health priority. In a phase I/II, placebo-controlled trial, healthy, HIV-1-negative adults were randomized to receive one of 5 vaccine regimens: LIPO-5 (combination of 5 lipopeptides) alone (250 μg), ALVA...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Vaccine Immunol
Autori principali: Frey, Sharon E., Peiperl, Laurence, McElrath, M. Juliana, Kalams, Spyros, Goepfert, Paul A., Keefer, Michael C., Baden, Lindsey R., Lally, Michelle A., Mayer, Kenneth, Blattner, William A., Harro, Clayton D., Hammer, Scott M., Gorse, Geoffrey J., Hural, John, Tomaras, Georgia D., Levy, Yves, Gilbert, Peter, deCamp, Allan, Russell, Nina D., Elizaga, Marnie, Allen, Mary, Corey, Lawrence
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2014
Soggetti:
Vaccines
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4248765/
https://ncbi.nlm.nih.gov/pubmed/25253665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.00450-14
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi